Industry News

• Johnson & Johnson announces offer to acquire Ci:z Holdings Co., Ltd.  Johnson & Johnson announced an agreement with Ci:z Holdings Co., a Japanese company focused on marketing, development and distribution of cosmetic and skincare products, to launch an all-cash offer to acquire all of the outstanding shares for ¥5,900 per share, or a total of ¥230 billion.
  October 23, 2018  
• Myo-inositol unlikely to reduce risk of eye complication in preterm infants  Contrary to results from earlier studies, the vitamin-like substance myo-inositol does not appear to prevent a potentially blinding complication of preterm birth and may even reduce rates of survival among preterm infants, suggests a study funded by the National Institutes of Health.
  October 23, 2018  
• Myriad announces publication of Foresight™ carrier screen clinical utility study  Myriad Genetics announced that results from a large clinical utility study using the Foresight™ Carrier Screen were published in the journal Genetics in Medicine. The key finding is that expanded carrier screening prompted changes that resulted in fewer births affected with serious genetic diseases.
  October 23, 2018  
• Neos Therapeutics licenses pipeline candidate for treatment of sialorrhea   Neos Therapeutics announced it has licensed NRX 101, a candidate for treatment of sialorrhea (excessive salivation or drooling) from NeuRx Pharmaceuticals. This candidate will now be known as NT0501 and is a new chemical entity and a selective muscarinic receptor antagonist.
  October 23, 2018  
• CEL-SCI receives $8 million from warrant exercises  CEL-SCI announced it has received just under $8 million through the exercise of warrants to purchase shares of the Company's common stock during the past 3 months. As of Oct. 22, 2018, CEL-SCI had 28,271,615 outstanding shares of common stock.
  October 23, 2018  
• Alder announces positive results from pharmacokinetic comparability study for eptinezumab  Alder Biopharmaceuticals announced positive results from a comparative PK study intended to support the comparability evaluation of the clinical supply for eptinezumab and its planned commercial supply. Eptinezumab is Alder’s lead investigational product candidate for migraine prevention.
  October 23, 2018  
• FDA grants Orphan Drug Designation to Omeros' OMS721 for treatment of HSCT-TMA  Omeros announced OMS721 has received orphan drug designation from the FDA for treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. OMS721 is Omeros’ lead human monoclonal antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
  October 23, 2018  
• Amneal announces approval and launch of clobazam tablets and clobazam oral suspension  Amneal Pharmaceuticals announced it has received FDA approval for a generic version of Onfi® (clobazam) tablets, 10 mg and 20 mg for oral use, CIV, and Onfi ® (clobazam) oral suspension, 2.5 mg/mL ,CIV.
  October 23, 2018  
• Xeris Pharma announces FDA acceptance of NDA filing for ready-to-use glucagon rescue pen  Xeris Pharmaceuticals announced its NDA for its ready-to-use, room-temperature stable liquid glucagon rescue pen for treatment of severe hypoglycemia in people with diabetes has been accepted for review by FDA. The FDA has assigned a PDUFA goal date of June 10, 2019.
  October 23, 2018  
• Stryker completes acquisition of Invuity, Inc.  Stryker announced completion of its acquisition of Invuity, Inc. Under the terms of the transaction, each outstanding share of Invuity common stock has been converted into the right to receive $7.40 in cash, without interest, subject to any required withholding taxes.
  October 23, 2018  

   (next 10 articles)